All In Biotech

Drug Trial Radar · NCT04432831

A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema

A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients With Diabetic Macular Edema

Last checked: Nov 20, 2026Latest source record: Feb 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,479

Actual

Start

Aug 5, 2020

Primary completion

Oct 11, 2023

Study completion Oct 11, 2023

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jun 16, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter long-term extension study designed to evaluate the long-term safety and tolerability of faricimab administered by intravitreal (IVT) injection at a personalized treatment interval (PTI) to participants who enrolled in and completed one of the two Phase III studies, GR40349 (NCT03622580) or GR40398 (NCT03622593), also referred to as the parent studies.

Conditions

  • Diabetic Macular Edema

Interventions

  • FaricimabDrug

    Faricimab will be administered by intravitreal (IVT) injection into the study eye according to the personalized treatment interval (PTI) dosing regimen.

  • Sham ProcedureOther

    The sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. The sham procedure will be administered to participants as appropriate during the first 16 weeks of this study in order to maintain the masking of the initial faricimab PTI.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and Severity of Ocular Adverse Events in the Study Eye, With Severity Determined According to Adverse Event Severity Grading ScaleTime frame: From the day of the first dose of faricimab until the end of the study (up to 108 weeks)
  2. Incidence of Ocular Adverse Events in the Fellow EyeTime frame: From the day of the first dose of faricimab until the end of the study (up to 108 weeks)
  3. Incidence and Severity of Non-Ocular Adverse Events, With Severity Determined According to Adverse Event Severity Grading ScaleTime frame: From the day of the first dose of faricimab until the end of the study (up to 108 weeks)

Locations

320 sites in 30 countries. Site status is shown where the registry gives one.

  • Barnet Dulaney Perkins Eye Center

    Mesa, Arizona

  • Retinal Research Institute, LLC

    Phoenix, Arizona

  • Arizona Retina and Vitreous Consultants

    Phoenix, Arizona

  • Retina Associates Southwest PC

    Tucson, Arizona

  • California Retina Consultants.

    Bakersfield, California

  • Retina-Vitreous Associates Medical Group

    Beverly Hills, California

  • Retinal Diagnostic Center

    Campbell, California

  • The Retina Partners

    Encino, California

  • Eye Medical Center

    Fresno, California

  • Retina Consultants of Orange County

    Fullerton, California

  • Southern California Permanente Medical Group

    Los Angeles, California

  • Northern California Retina Vitreous Associates

    Mountain View, California

  • East Bay Retina Consultants

    Oakland, California

  • Southern CA Desert Retina Cons

    Palm Desert, California

  • California Eye Specialists Medical group Inc.

    Pasadena, California

  • Retina Consultants, San Diego

    Poway, California

  • Retina Consultants of Southern California

    Redlands, California

  • Retinal Consultants Med Group

    Sacramento, California

  • West Coast Retina Medical Group

    San Francisco, California

  • Orange County Retina Med Group

    Santa Ana, California

  • California Retina Consultants

    Santa Barbara, California

  • California Retina Consultants - Santa Maria

    Santa Maria, California

  • Bay Area Retina Associates

    Walnut Creek, California

  • University of Colorado; dept of ophthalmology

    Aurora, Colorado

  • Retina Consultants of Southern

    Colorado Springs, Colorado

  • Colorado Retina Associates, PC

    Lakewood, Colorado

  • Retina Group of New England

    Waterford, Connecticut

  • Rand Eye

    Deerfield Beach, Florida

  • Retina Group of Florida

    Fort Lauderdale, Florida

  • National Ophthalmic Research Institute

    Fort Myers, Florida

  • Florida Eye Associates

    Melbourne, Florida

  • Retina Care Specialists

    Palm Beach Gardens, Florida

  • Retina Specialty Institute

    Pensacola, Florida

  • Fort Lauderdale Eye Institute

    Plantation, Florida

  • Retina Vitreous Assoc of FL

    St. Petersburg, Florida

  • Southern Vitreoretinal Assoc

    Tallahassee, Florida

  • Retina Associates of Florida, LLC

    Tampa, Florida

  • Southeast Retina Center

    Augusta, Georgia

  • Georgia Retina PC

    Marietta, Georgia

  • Retina Consultants of Hawaii

    ‘Aiea, Hawaii

Showing 40 of 320 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.